Literature DB >> 29962848

Overcoming resistance in a BRAF V600E-mutant adenocarcinoma of the lung.

T Schmid1, M Buess1.   

Abstract

We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib-trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib-trametinib can overcome vemurafenib resistance in a BRAF V600E-mutated adenocarcinoma of the lung.

Entities:  

Keywords:  Adenocarcinoma; BRAF; MEK; acquired resistance; dabrafenib; non-small-cell lung cancer; targeted therapy; trametinib

Mesh：

Substances：

Year:  2018        PMID： 29962848      PMCID： PMC6023556          DOI： 10.3747/co.25.3936

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  9 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Missense mutations of the BRAF gene in human lung adenocarcinoma.

Authors:  Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

3.  Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Authors:  Max Schreuer; Yanina Jansen; Simon Planken; Ines Chevolet; Teofila Seremet; Vibeke Kruse; Bart Neyns
Journal:  Lancet Oncol       Date:  2017-03-04       Impact factor: 41.316

Review 4.  BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

Authors:  E Sanz-Garcia; G Argiles; E Elez; J Tabernero
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

5.  Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Authors:  David Planchard; Tae Min Kim; Julien Mazieres; Elisabeth Quoix; Gregory Riely; Fabrice Barlesi; Pierre-Jean Souquet; Egbert F Smit; Harry J M Groen; Ronan J Kelly; B C Cho; Mark A Socinski; Lini Pandite; Christine Nase; Bo Ma; Anthony D'Amelio; Bijoyesh Mookerjee; C Martin Curtis; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2016-04-11       Impact factor: 41.316

6.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

7.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

8.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Authors:  David Planchard; Benjamin Besse; Harry J M Groen; Pierre-Jean Souquet; Elisabeth Quoix; Christina S Baik; Fabrice Barlesi; Tae Min Kim; Julien Mazieres; Silvia Novello; James R Rigas; Allison Upalawanna; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2016-06-06       Impact factor: 41.316

9.  Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.

Authors:  Monika Joshi; Shawn J Rice; Xin Liu; Bruce Miller; Chandra P Belani
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240
  9 in total
  1 in total

1.  Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.

Authors:  Alice Iezzi; Elisa Caiola; Arianna Scagliotti; Massimo Broggini
Journal:  BMC Cancer       Date:  2018-10-23       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.